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Granulomatous Inﬂammation in
Tuberculosis and Sarcoidosis: Does
the Lymphatic System Contribute to
Disease?
Tuberculosis and sarcoidosis are poten-
tially deadly diseasesmarked by the forma-
tion of granulomatous lesions in aﬀected
organs. An unexplained feature of gran-
ulomatous inﬂammation is its anatomi-
cal association with the lymphatic system.
Herein, it is explored how lymphatic tracks
interact with granulomas, and future chal-
lenges that remain to be addressed are
highlighted.
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Granulomatous Inﬂammation in Tuberculosis and
Sarcoidosis: Does the Lymphatic System Contribute
to Disease?
Karen C. Patterson,* Christophe J. Queval, and Maximiliano G. Gutierrez*
A striking and unexplained feature of granulomatous inﬂammation is its
anatomical association with the lymphatic system. Accumulating evidence
suggests that lymphatic tracks and granulomas may alter the function of each
other. The formation of new lymphatics, or lymphangiogenesis, is an adaptive
response to tumor formation, infection, and wound healing. Granulomas also
may induce lymphangiogenesis which, through a variety of mechanisms,
could contribute to disease outcomes in tuberculosis and sarcoidosis. On the
other hand, alterations in lymph node function and lymphatic draining may be
primary events which attenuate the risk and severity of granulomatous
inﬂammation. This review begins with an introduction of granulomatous
inﬂammation and the lymphatic system. A role of the lymphatic system in
tuberculosis and sarcoidosis is then hypothesized. With a focus on
lymphangiogenesis in these diseases, and on the potential for this process to
promote dissemination, parallels are established with the well-established
role of lymphangiogenesis in tumor biology.
1. Introduction: Infectious and Sterile
Granulomatous Diseases
The formation of granulomas is a distinct and striking response
of the immune system. Hubs of activity, granulomas engage in
immune surveillance and direct local immune responses. While
various types of cells, including CD4+ T cells, CD8+ T cells,
and B cells are associated with granulomas, macrophages are
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the most conspicuous and fundamental
cellular element of this lesion.[1] Cytokines
such as Tumor Necrosis Factor-alpha (TNF-
𝛼) promote the functional integrity of
granulomas,[2] which can wax and wane in
concert with disease activity. Resolution of
the granulomatous response presumably
occurs when antigen is eradicated or the
local immune response is altered and in-
ﬂammation resolved.
Granulomas are an important part of the
immune response to certain infections that
can eventually result in restriction of mi-
crobial spread. They may also contribute to
microbial killing, although the scope and
mechanisms of this process are poorly un-
derstood. On the other hand, vigorous gran-
ulomatous inﬂammation can lead to ﬁbrotic
and necrotic reactions which damage the
host.[1] The range of possible outcomes of
granulomatous inﬂammation is exempli-
ﬁed in leprosy, a common granulomatous
disease caused by infection with Mycobacterium leprae. An ex-
uberant inﬂammatory response in tuberculoid leprosy is associ-
ated with lowmicrobial burden but extensive damage of the host,
whereas weak granulomatous responses in lepromatous leprosy
are associated with rampant bacterial growth yet minimal col-
lateral damage.[3] In this review, we focus on granulomatous re-
sponses in tuberculosis and sarcoidosis, and explore the associa-
tion of granulomas and the lymphatic system.
Tuberculosis remains one of the deadliest human infectious
diseases, accounting for up to 2 million deaths annually.[4] In ad-
dition, a third of the global population is considered to be latently
infected and at risk for re-activation disease. Therefore, under-
standing the pathogenesis of microbial latency and re-activation
is a critical global health agenda. Human infection withmycobac-
teria, including the etiologic agent of tuberculosis,Mycobacterium
tuberculosis, is a potent trigger of granuloma formation. Tubercu-
loid granulomas are typically highly organized structures, com-
posed of a mix of macrophage phenotypes.[5] Macrophage popu-
lations in the granuloma include epithelioid histiocytes, marked
by abundant cytoplasm, and foamymacrophages with intracellu-
lar lipid accumulation. Alternatively, macrophages can coalesce
into multi-nucleated giant cells, also called Langhans’ cells. Be-
yond the bevy of macrophages, collections of lymphocytes in the
outer border are common, as is a ﬁbrotic layer beyond that inma-
ture granulomas (Figure 1).[6] Granulomas in tuberculosis can
be necrotic or non-necrotic, and often both types of lesions are
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Figure 1. The relationship between granulomas, lymphatic, and blood vessels. Granulomas in tuberculosis and sarcoidosis occur along lymphatic
tracks. In this model, a well-organized granuloma is hypothetically associated with both lymphatic and blood vessels. In the granuloma, the necrotic
core is surrounded by a layer of macrophages, with a slimmer outer ring of lymphocytes. The phenotype of macrophages in granulomas include foamy
macrophages, epithelioid histiocytes, and multi-nucleated giant cells. The potential function of lymphatic vessels in the delivery of antigen presenting
cells, other immune cells, and lymph to secondary lymphatic structures as well as the relationship with the blood vessels is also depicted.
present in infected tissues. When it occurs, central necrosis can
be expansive, leading to eﬀacement of normal structures.
In contrast to tuberculosis, sarcoidosis is a sterile granulo-
matous disease of unknown aetiology. The lungs and thoracic
lymph nodes are the most commonly aﬀected sites, although
many patients have widespread, multi-organ disease. Similar to
tuberculosis, macrophages are the primary cellular component
of sarcoid granulomas, which are typically large, well-formed,
and non-necrotic.[7]
Many of the salient clinical features of re-activation tubercu-
losis and sarcoidosis are similar. This includes an overlap of
presenting symptoms and chest imaging ﬁndings. Circulating
biomarkers and gene expression proﬁles also are similar, re-
ﬂecting shared immune response programs.[8–10] Given the pro-
inﬂammatory nature of these diseases, cutaneous anergy is a
seemingly paradoxical ﬁnding observed in both sarcoidosis and
tuberculosis. Necrotic granulomas on biopsy are most suggestive
of tuberculosis. However, in some cases the distinction between
tuberculosis and sarcoidosis can only be deﬁnitively established
via microbial studies which rule in or out the presence of my-
cobacterial species.
Granulomatous inﬂammation in both tuberculosis and sar-
coidosis has a distinct predilection for lymphatic tissue. In pa-
tients with widespread tuberculosis or sarcoidosis, lymph nodes
are the most common site of disease, although spleen and liver
involvement is frequently observed. In sarcoidosis, granuloma-
tous inﬂammation develops speciﬁcally along lymphatic tracks,
especially in the lung.[7,11,12] In an animal model of mycobacterial
disease, granulomatous inﬂammation also primarily occurred
along the lymphatic tracks of the lung.[13] In spite of this close
anatomical relationship, the potential contribution of the lym-
phatic system is not typically recognized in the disease models of
granulomatous inﬂammation, which emphasize the role of anti-
gen, macrophages, T cells, and pro-inﬂammatory cytokines. Yet,
accumulating evidence suggests that the lymphatic network may
have a role in the disease process of tuberculosis and sarcoidosis.
In the following sections, we explore this hypothesis, including
the potential impact of granuloma-mediated lymphangiogenesis.
We begin with a concise review of lymphatic development and
post-embryonic lymphatic remodeling.
2. Lifelong Lymphangiogenesis Is Supported
by Dynamic Lymphatic Endothelial Cells
The maintenance of a robust and dynamic lymphatic system is
essential to life. Embryonic lymphangiogenesis occurs via the es-
tablishment of lymphatic sacs which bud and separate from early
venous channels.[14] Centrifugal sprouting from these lymph sacs
results in a network of lymphatic vessels, constituting a mix of
blind-ended capillary beds and larger collecting vessels. From the
time of their initial development, lymphatic vessels are anatom-
ically coupled to the venous network. In this way, they are well-
positioned to remove excess interstitial ﬂuid which accumulates
as a result of vascular hydrostatic forces.
A seemingly invisible network, the daily circulation of lymph
through human lymphatic vessels parallels that of blood ﬂow
through the blood vascular system. Yet, lymphatic clearance is
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Figure 2. Contribution of macrophages to the process of lymphangiogenesis. The replication of specialized LECs (tip cells) appears to be the pre-
dominant mechanism by which lymphatic networks elongate. Macrophages support post-embryonic lymphangiogenesis through the production of
pro-lymphangiogenic cytokines, or via transdiﬀerentiation into lymphatic endothelial cells which integrate into developing lymphatic vessels.
not uniform throughout the body. In contrast to blood ﬂow, lym-
phatic ﬂow is not supported by a single systemic pump. Exter-
nal muscle contractions promote the movement of ﬂuid through
lymphatic capillaries. In contrast, movement through larger ves-
sels is aided by one-way valves and the contraction of smooth
muscle cells investing lymphatic vessels.[15] Beyond reclaimed
interstitial ﬂuid, central lymphatic vessels deliver intestinal fats
and associated nutrients to circulating blood.[14] They are also a
conduit for immune cell traﬃcking, serving the migration of im-
mune cells to secondary lymph organs where adaptive immune
responses develop.
Lymphatic endothelial cells (LECs) are the fundamental cel-
lular structure of lymphatic vessels. Functionally distinct from
blood endothelial cells, human LECs are characterized by the
expression of speciﬁc markers such as lymphatic vessel en-
dothelial hyaluronan receptor-1 (LYVE-1) and podoplanin, as well
as the Prospero homeobox protein 1 (PROX-1) transcription
factor. PROX-1 is essential for the lymphatic identity of LECs
and drives expression of pro-lymphangiogenic genes.[16–21] LECs
are also characterized by speciﬁc metabolic features. Endothelial
cells have relatively low mitochondrial counts[22] and cytoplas-
mic glycolysis is the primary mechanism of adenosine triphos-
phate (ATP) generation. Glycolysis is ineﬃcient for ATP genera-
tion compared to mitochondrial oxidative phosphorylation.[23–26]
Yet, it favors the ability of LECs to generate suﬃcient amounts
of ATP even when oxygen tensions are low, as can occur in tu-
mor or granuloma environments.[27] During lymphangiogenesis,
LECs also engage in fatty acid 𝛽-oxidation. This supports mito-
sis, where by-products of fatty acid oxidation become precursor
molecules for nucleotide synthesis. Inhibition of fatty acid ox-
idation in LECs has a minor eﬀect on energy production and
redox homeostasis, but strongly impairs the deoxynucleotides
synthesis required for DNA replication during lymphatic ves-
sel growth.[28] Additionally, fatty acid derived acetyl-CoA is a co-
factor for enzymes which epigenetically regulate genes, includ-
ing those expressed under control of the transcription factor
PROX-1. In this way, acetyl-CoA promotes the selective transcrip-
tion of pro-lymphangiogenic genes such as vascular endothelial
growth factor receptor (VEGFR) 3 which helps maintain LEC
identity.[29]
The ability to regenerate or remodel lymphatic vessels is es-
sential to life. The expansion and reconstruction of vessels con-
tribute to the dynamic maintenance of a functional lymphatic
network.[30] Distal cells in budding branches develop a “tip cell”
phenotype, providing directional guidance during growth of lym-
phatic vessels.[31] Signaling through the VEGFR3-VEGF ligand
pathway is implicated in the transformation of distal cells to a
tip cell phenotype.[31] Stabilization of budding vessels is achieved
by adhesionmolecules whichmechanically couple LECs with the
extracellular matrix.
The replication of LECs enables post-embryonic
lymphangiogenesis.[32] Circulating progenitor cells also may
incorporate into lymphatic vessels undergoing repair or growth
(Figure 2). In explanted human kidneys, circulating (male)
progenitor cells were found to be integrated into the lymphatic
vessels of (female) donor kidneys.[33] A variety of progenitor
cell types have been implicated in lymphangiogenesis.[32] In
a study of labeled donor stem cells in irradiated mice, only
haematopoietic stem cells, and not more lineage committed
stem cells, served as precursor cells for LECs.[34] However,
ﬁndings from a variety of other studies most strongly implicate
myeloid derived cells as the primary source, with the assumption
that circulating progenitor cells can access inﬂamed tissues and
acquire a mature macrophage phenotype. For example, in a
study of irradiated mice, donor bone marrow derived CD11b+
macrophages adopted a LEC phenotype and integrated into
growing lymphatic vessels at sites of wound inﬂammation.[35]
3. Macrophages Are Critical for Post-Embryonic
Lymphangiogenesis
In a variety of ways, macrophages play a critical role in post-
embryonic lymphatic remodeling. In animal models of mechan-
ical injury and infection, macrophage suppression is associ-
ated with decreased lymphangiogenesis.[35,36] Similarly, in tumor
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models the depletion of macrophages is associated with a de-
crease in lymphatic vessel density.[37] Several mechanisms have
been invoked to account for the role of macrophages in lymphan-
giogenesis (Figure 2).Macrophages are a source of VEGF ligands,
which promote the growth of sprouting lymphatic vessels.[36,38,39]
In one study, a reduction in lymphangiogenesis was achieved
equally by suppression of the VEGF-C/VEGFR3 axis directly or
by macrophage depletion.[40] However, the paramount contribu-
tion of macrophages to VEGF ligand production has been ques-
tioned, and in tumor models may be less critical.[32,37] Similar
to what has been observed in angiogenesis,[41] macrophages also
may have an organizational role in lymphangiogenesis. In a study
of diaphragm lymphatics, the deletion ofmacrophages prevented
their co-localization at the tips of developing lymphatic vessels,
and was associated with more disorganized vessel branching.[42]
The mechanisms of how macrophages regulate sprouting are
still poorly characterized. Nonetheless, these ﬁndings highlight
the potentially multifaceted contribution of macrophages to a dy-
namic lymphatic network.
Crucially, a variety of ﬁndings indicate thatmacrophagesmain-
tain a high degree of plasticity and are able to transdiﬀerenti-
ate (undergo transcriptomic reprogramming) into LECs. Cells ex-
pressing both macrophage and LEC markers were present in the
vicinity of and within lymphatic vessels in an animal model of
wound inﬂammation.[35] Similarly, human monocytes expressed
lymphatic markers and developed morphologic features of LECs
when cultured with VEGF-containing media.[33] VEGF signaling
appears to be a strongly determining step in the transdiﬀeren-
tiation process, at least initially, and VEGFR-3 suppression with
either a decoy receptor or RNA silencing abrogated the transdif-
ferentiation of macrophage to LECs.[32] VEGFR-3 expression on
macrophages corresponds with up-regulation of VEGF-C, repre-
senting the potential for a self-amplifying autocrine loop that sup-
ports transdiﬀerentiation.
Transdiﬀerentiated macrophages appear capable of integrat-
ing into spouting lymphatic vessels. In an in vivo corneal injury
mouse model, cells expressing both lymphatic and macrophage
markers were integrated into newly generated lymphatic
vessels.[35,43] When Green Fluorescent Protein (GFP)-labeled
transdiﬀerentiated macrophages were cultured with immortal-
ized murine lymphatic cells, GFP+macrophages integrated into
developing vessel-like structures.[37] Furthermore, the integra-
tion of macrophages occurred speciﬁcally at the tips and branch-
ing points, suggesting that these cells support sprouting from
pre-existing branches. Tet, transdiﬀerentiated macrophages may
also participate in the de novo formation of lymphatic tracks. Ex
vivo CD11b+ alveolarmacrophages from patients with idiopathic
pulmonary ﬁbrosis demonstrated a propensity to aggregate and
form structures resembling nascent lymphatic vessels.[44] Simi-
larly, transdiﬀerentiated murine macrophages in tissue culture
clustered together and formed early vessel-like structures.[35] The
clinical importance of these ﬁndings remains unclear, as de novo
vessel formation is generally considered a minor contribution to
lymphatic remodeling. However, in kidneys aﬀected by rejection-
induced inﬂammation, in which lymphatic vessel density is sub-
stantially increased, recipient-derived progenitor cells accounted
for, on average across several samples, 13% of vessels. In contrast
to recruited myeloid progenitor cells, the role of long-term tissue
resident macrophages in lymphangiogenesis is less clear.
After a phase of a dual-cell phenotype, transdiﬀerentiated
macrophages may evolve toward a fully diﬀerentiated LEC state.
In a study of chronic kidney rejection, in which tissue sampling
occurred years after the initial inﬂammatory events, recipient
progenitor cells which had integrated into the lymphatic vessels
of donor kidneys were negative for myeloid markers.[33] The au-
thors hypothesized that cells had undergone programmed loss of
myeloid markers. In one of the only studies to capture this phe-
notypic progression, transdiﬀerentiated bone marrow-derived
macrophages in culture not only began to express lymphatic
markers but also down-regulated their expression ofmacrophage
markers.[37]
4. Lymphangiogenesis Is a Double-Edged Sword
in Disease
A variety of diseases trigger lymphangiogenesis, and cancer has
been the most widely studied in this context. The dissemination
of tumor cells via peritumoral lymphatic vessels and the upregu-
lation of lymphangiogenesis in regional lymph nodes appear to
be important mechanisms of tumor spread.[45,46] Animal models
and human studies strongly link tumor-associated lymphangio-
genesis with poor outcomes, including reduced survival.[46] Lym-
phangiogenesis also is observed in a variety of chronic infections,
including Human Immunodeﬁciency Virus (HIV), Herpes Sim-
plex Virus (HSV), and leishmaniasis.[47–49] In contrast to the detri-
mental relationship between lymphangiogenesis in cancer, an
expanded lymphatic network during infection facilitates immune
cell traﬃcking to infected tissues and helps mobilize the associ-
ated increase in interstitial ﬂuid. In this way, lymphangiogenesis
also contributes to tissue regeneration, leading to improved
outcomes following wound and ischemic injury events.[43,50]
Granulomatous diseases also appear capable of promoting
lymphangiogenesis. In mice infected with the attenuated vac-
cine strain Bacillus Calmette-Guerin (BCG), lymphangiogen-
esis was observed in infected liver.[51] Moreover, lymphatic
vessels co-localized to areas of granulomatous inﬂammation.
Similar ﬁndings were observed in lungs infected with Mycobac-
terium tuberculosis.[51] Lymphangiogenesis also appears to be up-
regulated in sarcoidosis. In one study, over half of granulomas
from lung biopsy samples were associated with one or more lym-
phatic vessels.[52] In contrast, blood capillaries were infrequently
observed near granulomas, suggesting that lymphangiogenesis
was not merely a by-product of angiogenesis. Lymphatic vessels
were signiﬁcantly and selectively associated with large granulo-
matous lesions, raising the question of a possible role for lesion-
triggered hypoxia in promoting lymphangiogenesis. In another
study, 67% of lung sarcoid granulomas had a lymphatic vessel
in close proximity to the granuloma border.[53] Most of these ves-
sels had an irregularmorphology consistent with post-embryonic
lymphangiogenesis. In a study of cardiac lymphatics, biopsy sam-
ples from patients with cardiac sarcoidosis demonstrated an in-
crease in the number of lymphatic vessels compared to non-
sarcoidosis controls.[54] Again, vesselmorphologies in sarcoidosis
samples were suggestive of post-embryonic lymphangiogenesis.
As a mechanistic link for these ﬁndings, elevated levels of circu-
lating and tissue VEGF have been observed in both tuberculosis
and sarcoidosis.[53,55–57]
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5. More than a Passive Conduit: Lymphatic Tracks
May Modulate Granulomatous Disease
The anatomical relationship between granulomas with the
lymphatic system and recent ﬁndings linking granulomatous
inﬂammation with lymphangiogenesis underpin the hypothesis
that the lymphatic network may contribute to the pathophysiol-
ogy of granulomatous diseases. In this section, we explore two
questions about the speciﬁc functional impact of the lymphatic
system in tuberculosis and sarcoidosis. In the ﬁrst, we also
speculate about the role of macrophages linking granulomas to
the lymphatic system.
5.1. Does Lymphangiogenesis Promote the Dissemination
of Granulomatous Disease?
The impact of lymphangiogenesis in granulomatous disease is
unclear. However, tumors may serve as an informative model
from which to draw inferences for granuloma biology. Like
tumors, oxygen tension is low in the center of expanding
granulomas,[27] and anaerobic metabolism which supports the
proliferation of LECs during tumor-associated lymphangiogene-
sis may also support lymphangiogenesis associated with expand-
ing granulomas. Also similar to cancer, the extent of “metastatic”
disease in tuberculosis and sarcoidosis is associated with long-
term outcomes. These and other parallels between malignant
tumors and granulomas, and between cancer and granuloma-
tous inﬂammation more broadly, raise the question of whether
lessons from lymphangiogenesis in cancer apply to granuloma-
tous inﬂammation. Speciﬁcally, does an expanded network of
lymphatic vessels contribute to the dissemination of tuberculosis
and sarcoidosis? Haematogenous spread is commonly invoked
for multi-organ tuberculosis.[58] However, several factors argue
against a simplemodel of haematogenous spread. In non-miliary
re-activation tuberculosis, a strong predilection for upper lung
zone involvement is observed despite low blood ﬂow rates relative
to lower lung zones. Even in miliary pulmonary tuberculosis,[59]
in which disease is attributed to haematogenous spread, the lym-
phatic tracks are often aﬀected. These observations suggest that
regional spread of tuberculosis via lymphatics needs to be con-
sidered during disease progression.[12] While biologically plau-
sible, the role of lymphatics during dissemination remains to
be demonstrated experimentally. In contrast to tuberculosis, the
mechanism(s) of multi-focal sarcoidosis are virtually unexplored.
It is likely, though, that mechanisms of disease spread are simi-
lar, particularly as the internal organs most at risk of multi-organ
involvement in tuberculosis and sarcoidosis are nearly identical.
Another similarity between tumors and granulomas is the
central role of macrophages in orchestrating local immune re-
sponses. While tumor cells are a source of VEGF-C, the de-
velopment of a population of tumor-associated macrophages
(TAMs) also promotes lymphangiogenesis. TAMs derive from
circulating macrophages[60] and have been linked to an in-
crease in peritumoral lymphatic vessels. In the tumor micro-
environment, a subset of TAMs acquire the ability to express
VEGF-C.[60] TNF-𝛼 is one of the key tumor-associated cytokines
driving TAMs toward a VEGF-C-expressing phenotype. In ad-
dition to pro-lymphangiogenic factors, TAMs can produce and
secrete extracellular matrix remodeling mediators (metallopro-
teinases) which further support tumor vascularisation, includ-
ing lymphangiogenesis.[60–64] Several studies have demonstrated
that the secretion of factors such asmatrixmetalloproteinase-9 or
VEGF by multi-nucleated giant macrophages is associated with
vascular invasion of bone tumors during cancer metastasis.[65–67]
However, the involvement of multi-nucleated giant cells in the
vascularization of granuloma is still not clearly established. Fi-
nally, while the integration of TAMs directly into peritumoral
lymphatic vessels has not been demonstrated, this possibility is
suggested by the dual expression of macrophage and LEC mark-
ers, such as LYVE-1 and VEGF-R3.[60]
5.2. Does the Lymphatic System Impair Antigen Clearance
and Microbial Eradication?
Lymph nodes are the most common site of active tuberculosis,
and granulomas persist within lymph nodes in latent tuberculo-
sis. These key clinical features support the notion that mycobac-
terial infection is primarily a lymphatic disease.[12] In this model,
re-activation reﬂects failure of microbial eradication and lymph
node containment. This failure may be due to lymph node spe-
ciﬁc factors. In amacaquemodel of infection, lymph node granu-
lomas were less protective againstM. tuberculosis than lung gran-
ulomas, containing a larger number of live bacteria and serving
as a reservoir for the long persistence of bacilli.[68] The reasons
for this are unclear, although ﬁndings in cancer may be relevant,
where immunosuppressive cytokines are elevated in draining
lymph nodes, while lymphocyte and dendritic cell populations
are reduced.[69] Whether altered immunocompetence in lymph
nodes also occurs in tuberculosis and contributes to the persis-
tence of infected granulomas remains to be determined. Other
factors speciﬁc to the local environment, including local hypoxia
and metabolic pressures, could also contribute to regional and
tissue diﬀerences in lymphatic function.
Another possibility is that the lymphatic vasculature con-
tributes to microbial persistence. Recently, M. tuberculosis bacte-
ria were found within nodal LECs.[70] It remains unclear if these
LECs can harbor tuberculosis bacilli in the long-term. If LECs are
infected during latent tuberculosis, these cells may contribute to
the phenomenon of higher post-treatment relapse rates in extra-
pulmonary tuberculosis.[71]
The function of non-nodal lymphatic vessels may also have a
role in granulomatous disease. In pulmonary sarcoidosis, the for-
mation of granulomas occurs nearly exclusively along lymphatic
tracks. This suggests that antigen is found within or around lym-
phatic vessels, and that T cells and macrophages are recruited
to these areas. Sluggish lymphatic ﬂow rates may contribute to
the retention of immune cells.[72,73] Flow rates are largely deter-
mined by the volume of reclaimed interstitial ﬂuid, which is a
function of pulmonary vascular (hydrostatic) pressures. These
pressures, and thus lymphatic ﬂow rates, are lowest in the upper
lung zones. Regional diﬀerences in lymphatic ﬂow in the lung
have been invoked to account for the upper zone predominance
of tuberculosis.[74] However, rather than enhanced immunity
from the retention of immune cells, low ﬂow conditions could
facilitate lymphatic vessels becoming a site of immune privilege.
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Alternatively, peri-lymphatic granulomatous inﬂammation could
obstruct ﬂow, converting low ﬂow states into no-ﬂow states.
Pathological conditions which alter lymphatic clearance atten-
uate the risk of tuberculosis, and support lymphatic congestion
as a risk factor for granulomatous disease. For example, silico-
sis is associated with an elevated risk of pulmonary tuberculosis.
The ﬁbrosis of draining lymph nodes aﬀected by silicosis even-
tually leads to the obstruction of aﬀerent lymphatic vessels in the
lungs.[75,76] Pulmonary (valve or artery) stenosis similarly results
in reduced lymphatic ﬂow through the lung, and is associated
with an increased risk of pulmonary tuberculosis. Conversely,
aortic stenosis raises pulmonary arterial pressures, which leads
to increased lymphatic ﬂow, and is associated with a reduced risk
of pulmonary tuberculosis. As the prevalence of sarcoidosis is
substantially lower than that of tuberculosis, data correlating the
impact of valvular disease on disease risk are not available. How-
ever, similar to tuberculosis, sarcoidosis is a strikingly upper lung
zone predominant disease, and lymphatic ﬂow rates may con-
tribute to this phenomenon.
6. Important Considerations and Future Challenges
To further elucidate the role of the lymphatic system in granulo-
matous disease, several speciﬁc research agendas are worth con-
sidering. Perhaps the most urgent need is to determine the clin-
ical relevance of lymphangiogenesis in granulomatous inﬂam-
mation, particularly in regard to its role in sustaining or abro-
gating immune responses, and in potentiating disease spread.
Lessons from angiogenesis should be highly relevant to this pur-
suit. Through the discovery of VEGF signaling and endothelial
cellmetabolism, advances in understanding inﬂammatory vascu-
larization in angiogenesis have provided new therapeutic targets
in cancer.[77,78] Similarly, inhibition of VEGF signaling promotes
the normalization of blood vessels, and improves the bioavail-
ability drugs and eﬃcacy of treatment in inﬂammatory angio-
genesis associated with tuberculoid granulomas.[57,79] Accumu-
lating evidence suggests that understanding the consequences of
lymphatic remodeling holds similar therapeutic potential. Drugs
that promote or impair lymphangiogenesis could complement
the action of anti-microbial drugs in tuberculosis, or immune-
suppressing medications in pathogen-free sarcoidosis. The dis-
covery of pro-lymphangiogenic factors in the past 20 years has
facilitated a surge in lymphatic research. Drawing on those re-
sults, the potential to target lymphangiogenesis for disease con-
trol is a very attractive possibility. While there are currently no
drugs approved which target lymphangiogenesis in cancer or
other diseases, early animal studies are underway and human
studies are eagerly anticipated. VEGF, epidermal growth factor
receptor, ﬁbroblast growth factor, and platelet-derived growth fac-
tor pathways have been identiﬁed as potential targets.[80] Similar
to challenges encountered with cancer treatment, the problem
with common pathways implicated in angiogenesis will need to
be addressed and avoided.
The relationship between granulomas and lymphangiogene-
sis may depend on the speciﬁc tissue environment. For exam-
ple, granuloma-driven lymphangiogenesis may not be the same
in lymph nodes versus lung tissue. The cytokine milieu, extra-
cellular matrix components, and local immune cells vary across
tissue microenvironments, and may aﬀect lymphangiogenesis
potential. Human studies can be diﬃcult, although lymphatic-
focused histopathology and tissue culture studies have been
fruitful methodologies to begin to understand the impact of tis-
sue environment.
The role of macrophage phenotype is relatively unexplored
in granulomatous inﬂammation. In cancer, TAMs have im-
munosuppressive properties similar to alternatively activated
macrophages.[81] TNF-𝛼 helps further polarize TAMs to acquire a
lymphangiogenesis-promoting phenotype.[82] TNF-𝛼 is one of the
signature cytokines in granulomatous inﬂammation, and TNF-
𝛼 inhibitors are used therapeutically in sarcoidosis. Weakened
granuloma integrity is often invoked as the mechanism of ac-
tion, but this assumption has been challenged.[83] Given the role
of TNF-𝛼 in cancer-related lymphangiogenesis, it will be instruc-
tive to determine the eﬀect of TNF-𝛼 on lymphangiogenesis in
sarcoidosis and tuberculosis.
Further clariﬁcation of the role of macrophage transdif-
ferentiation in lymphangiogenesis is needed. The process of
macrophage transdiﬀerentiation shares features with epithelial
transdiﬀerentiation,[84] in which epithelial cells undergo tran-
scriptional reprogramming and transition to a mesenchymal
phenotype. Transdiﬀerentiated epithelial cells lose cell-cell ad-
hesion properties and gain the capacity to replicate and mi-
grate. This process, triggered by cytokines released from matrix
cells in the setting of tissue injury, serves tissue repair needs.
Lessons from epithelial transdiﬀerentiation[84] may be relevant
tomacrophage function in granulomatous inﬂammation. Specif-
ically, it will be instructive to deﬁne the extent of macrophage
reprogramming, and determine the contribution of macrophage
transdiﬀerentiation to lymphangiogenesis, wound repair, and ﬁ-
brotic responses.
Beyond their role in lymphangiogenesis, understanding how
granuloma macrophages interface with lymphatic structures is
also important. Macrophages do not typically traﬃc through lym-
phatic vessels, yet granulomatous inﬂammation in tuberculosis
and sarcoidosis occurs in the anatomical distribution of lym-
phatic tracks. The spatial relationship of granulomas to lym-
phatic vessels needs to be more precisely determined. Localiz-
ing granulomas to the inside or outside of the lymphatic lumen
is important for understanding how lesion micro-environments
aﬀect pathophysiology and may have implications for drug
delivery.
Another unmet need is a better understanding of the role of
LECs in granulomatous inﬂammation. The view of LECs as ele-
ments of a passive conduit has signiﬁcantly changed in the last
few years. Accumulating evidence suggests that LECs modulate
immune responses in response to infection.[85] Deﬁning the role
LECs in trans-endothelial leukocyte migration[86] and cytokine
signaling in granulomatous inﬂammation is needed. In addi-
tion, determining whether LECs participate in microbial seques-
tration in tuberculosis has important therapeutic ramiﬁcations.
It is tempting to speculate that LECs could also participate in
the sequestration of antigen in sarcoidosis. In a viral infection
model, LECs were found to harbor antigen long after viral eradi-
cation, and participated in the delivery of antigen to antigen pre-
senting cells.[87] Antigen presentation by LECs promotes anergic
responses,[87] which may be relevant to the clinical phenomenon
of anergy observed in sarcoidosis and tuberculosis.
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7. Conclusion
The role of the lymphatic system in the pathogeneses of granu-
lomatous diseases such as tuberculosis and sarcoidosis remains
understudied. In this review, we have explored several fundamen-
tal and unresolved questions regarding this relationship, high-
lighting ﬁndingswhich support the hypothesis that the lymphatic
system contributes to the pathogenesis of granulomatous dis-
ease. Recent studies suggest that LECsmay have direct microbial
contact in tuberculosis, and lymphatic vessel function may con-
tribute to the promotion and spread of granulomatous diseases.
Understanding the relationship between lymphatics and granu-
lomatous inﬂammation has important therapeutic implications,
and further research in this domain is eagerly anticipated.
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